Diabetes drug may shield lungs from cancer in High-Risk patients
NCT ID NCT07332156
First seen Jan 12, 2026 · Last updated May 09, 2026 · Updated 19 times
Summary
This study looked at medical records of over 21,000 adults with type 2 diabetes and COPD to see if a class of diabetes drugs called SGLT2 inhibitors could lower the chance of developing lung cancer compared to another diabetes drug class, sulfonylureas. Participants did not need to do anything new—researchers simply analyzed existing health data. The goal was to find out if SGLT2 inhibitors offer extra protection against lung cancer in this high-risk group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.